Celularity, Inc.
Celularity, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Celularity, Inc..
Celularity, Inc. is a company.
Key people at Celularity, Inc..
# High-Level Overview
Celularity Inc. (NASDAQ: CELU) is a clinical and commercial-stage biotechnology company developing off-the-shelf allogeneic cell therapies and biomaterial products derived from the postpartum placenta.[1][2] The company addresses aging-related and degenerative diseases, cancer, and immune disorders by leveraging placental-derived cells including mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and natural killer (NK) cells.[2][3] Celularity's core mission is to deliver accessible, affordable, and scalable cellular medicine solutions by harnessing the placenta's unique biology and ready availability.[2][4] The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking, with therapeutic programs targeting conditions such as diabetic foot ulcers, Crohn's disease, facioscapulohumeral muscular dystrophy, and osteoarthritis.[1]
The company serves patients with serious unmet medical needs while also producing and commercializing surgical and wound care biomaterial products under brands like Biovance and Rebound.[1] Celularity's growth momentum is supported by 15+ active and completed clinical trials, strategic partnerships with major pharmaceutical companies including Regeneron Pharmaceuticals and Sorrento Therapeutics, and a purpose-built 150,000 square-foot manufacturing and research facility staffed by over 100 specialized scientists and engineers.[2][4]
# Origin Story
Celularity's roots trace back to Anthrogenesis, founded in 1998, establishing two decades of foundational science in cellular medicine.[4] The company evolved significantly through a 2002 merger with Celgene, which provided substantial resources and pharmaceutical expertise.[4] In 2017, Celularity was spun out as an independent entity, and the company achieved public status in 2021, marking its transition to a clinical and commercial-stage enterprise.[4]
Dr. Robert Joseph Hariri, M.D., Ph.D., serves as Founder, Chief Executive Officer, and Chairman, bringing deep expertise in regenerative medicine and cellular therapeutics.[1] The company's leadership team includes seasoned cellular medicine innovators with extensive experience in clinical development and regulatory approval.[2] This experienced management structure reflects Celularity's evolution from a research-focused entity into a company capable of navigating complex regulatory pathways and scaling manufacturing operations.
# Core Differentiators
# Role in the Broader Tech Landscape
Celularity operates at the intersection of two transformative biotech trends: the shift toward off-the-shelf allogeneic cell therapies and the growing focus on aging-related and degenerative disease treatment.[2][3] The company's timing is advantageous as regulatory pathways for cell therapies mature, manufacturing costs decline, and healthcare systems increasingly recognize the economic value of regenerative medicine solutions.
The placental-derived approach addresses a critical bottleneck in cellular medicine: scalability and cost. Traditional autologous therapies require patient-specific manufacturing, limiting accessibility and driving up costs. Celularity's allogeneic platform sidesteps these constraints, positioning the company to influence how the broader industry approaches cell therapy manufacturing and commercialization.[2][4]
By developing both therapeutic programs and commercial biomaterial products, Celularity bridges the gap between early-stage innovation and near-term revenue generation—a model that strengthens its competitive position within the regenerative medicine ecosystem and demonstrates the viability of placental-derived therapeutics to investors and competitors alike.
# Quick Take & Future Outlook
Celularity is positioned to become a cornerstone player in the next wave of cellular medicine, particularly as regulatory approval pathways for cell therapies accelerate and healthcare systems demand cost-effective solutions for aging-related diseases. The company's success hinges on advancing its clinical pipeline—particularly PDA-001 and PDA-002—through regulatory milestones while scaling manufacturing to meet commercial demand.
The convergence of demographic aging, rising healthcare costs, and maturing cell therapy science creates a favorable environment for Celularity's mission. As the company matures from clinical to commercial stage, its influence will likely extend beyond its own pipeline: successful regulatory approvals and manufacturing scale-up could validate the placental-derived cell therapy model for the broader industry, potentially reshaping how competitors approach cell sourcing and production economics. The next 2-3 years will be critical in determining whether Celularity can translate its scientific foundation and manufacturing infrastructure into sustained commercial success.
Key people at Celularity, Inc..
